DEKA
31.1.2024 16:01:35 CET | Business Wire | Press release
DEKA, an Italian subsidiary of the El.En. Group, listed on the Eurostar Next of Borsa Italiana (ELN.MI), specialized in the development and production of pioneering Energy Based devices for aesthetics and surgery, on the occasion of the 25th IMCAS World Congress, which will be held in Paris from February 1-3, has announced the launch of 4 new laser platforms which integrate the “PRO” line, presented during the World Congress of Dermatology (WCD) held in Singapore last July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131482600/en/
(Photo: DEKA)
After the success obtained in the US and Canada, DEKA, with its laser systems, among which the very famous lunch-time CoolPeel® treatment for face rejuvenation, and epilation is now introducing the TETRA PROTM, MOTUS PROTM, SMARTXIDE PROTM and TOROTM platforms to the market.
With these new solutions DEKA transforms traditional dermatology laser technology paradigms, aesthetic medicine and dermatologic surgery, opening them to new practical frontiers.
Riccardo Stocchi – The company’s Innovation Manager stated: “The enthusiasm for the success we obtained with the PRO line and the ability to anticipate physicians’ requests, have turned, once again, into DEKA’s ability to create innovation, paying close attention to product positioning and correct segmentation of the reference market, responding with breakthrough technologies, which provide enormous benefits to both operators and patients. The road marked by DEKA, which has invested substantially in research and development and clinical research, obtaining extraordinary results, highlights, besides high efficacy and safety standards, maniacal attention to detail, from equipment design to software usability, with more and more innovative graphic user interfaces, which are absolutely intuitive and user friendly".
Paolo Salvadeo, DEKA’s CEO and El.En.’s General Manager, echoes Mr. Stocchi by adding: "These four new laser solutions, which see the light after few months from the launch of the PRO line, are the umpteenth demonstration of the efficacy of our organizational and R&D model. The path is marked. Thanks to DEKA’s strong aid, our group, in the medical segment, not only wishes to assert itself as the first player in the medical laser segment worldwide, but also to prospectively maintain a strong leadership position with regard to the market and competition. It is a fast-running machine, which we have no intention of slowing down".
Talking specifically about the four DEKA novelties, TETRA PROTM carries on the success seen by the birth of the “CoolPeel®” treatment/phenomenon in the US. TETRA PROTM, with its 40W of power, is the evolution of the 30W “SmartXide Tetra” CO2 laser, with a broader scanning area and treatment time reduction by 25%. The new “TETRA MOVEO” scanning mode also allows for treatment time reduction of the Made in the USA “CoolPeel®”. The ability to execute different treatments, from traditional and fractional rejuvenation, to various types of scar tissue, also deep, ultrafast vaporisations and other treatments which fall within various disciplines, completes the versatility of this new technology.
MOTUS PROTM is the latest evolution of the Motus line, Alexandrite laser and Nd:YAG, which has revolutionized the paradigms of epilation thanks to its high efficacy and very high comfort for the patient, also opening itself up to vascular treatments, up to the latest Made in the USA “MOVEO GLO”, which offers a complete face treatment, in the same session, to achieve optimal results at pigmentary, vascular and chrono-photo aging level. The “3 in 1” treatment with “GLO(W)” effect.
New design, more peak power, handled by a new software and mitigated by a new cooling system to carry forward the worldwide success in epilation signed by DEKA, are only a few of the novelties of the MOTUS PROTM technology.
Going back to CO2 Laser technology, SmartXide PROTM replicates the success of its predecessor, SmartXide DOT, the first fractional laser on the market, which has obtained success the world over, in particular in the United States, also known for periocular and blepharoplasty treatments.
Another important novelty is TOROTM, the laser device that the market had long been waiting for to act on more fronts: Spots, tattoos, rejuvenation, ranging from scar tissue to toning, all the way to the DEKAPeel treatment, to quickly intervene on dilated pores and obtain general improvement of cutaneous texture.
2 wavelengths, 1064 and 532 nm Q-Switched, and a third, 785nm, operating in the picosecond range, guarantee treatment efficacy and safety. TOROTM has been engineered especially for those skin types, among which Asian ones, which may benefit from this ultrafast coherent radiation, in terms of treatment efficacy and safety. By means of a pre-set database, which offers several clinical cases and a guided path throughout the various parameters which involve several targets (spot depth, tattoo color, typology of benign pigmented lesions, rejuvenation type and toning), TOROTM guides the physician, whilst guaranteeing treatment efficacy and safety.
Information on DEKA M.E.L.A.
DEKA M.E.L.A. is a subsidiary of the EL.EN. multinational Group which has been the leader in the laser work for 40 years.
This Italian company, headquartered in Florence, has its roots in a culture whose dominant characteristic is excellence of thought. Thanks to its priceless cultural heritage and its unique historical background, DEKA enshrines a promise of universal value in its vision: Transforming each scientific discovery into a solid benefit for physicians and patients, and translate each technological innovation into ongoing improvement in its product and services range to ameliorate the quality of people’s lives.
DEKA means reaching perfection and excellence and it is “10”, the perfect number according to the philosopher and mathematician Pythagoras.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131482600/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 03:00:00 CEST | Press release
Online sales outpace in-store by 6x as digital-first and AI-influenced commerce accelerates globally NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales,
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 15:26:00 CEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 15:25:00 CEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
